es and smoke-free products. Since 2008, PMI has invested over USD 14 billion to develop, scientifically substantiate, and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In 2022, PMI acquired Swedish Match—a leader in oral nicotine delivery—creating a global smoke-free champion led by the companies’IQOSandZYNbrands. Following a robust science-based review, the U.S. Food and Drug Administration has authorized the marketing of Swedish Match’sGeneralsnus andZYNnicotine pouches and versions of PMI’sIQOSdevices and consumables—the first-ever such authorizations in their respective categories. Versions ofIQOSdevices and consumablesandGeneralsnus also obta
=*=*=*=*=*=
当前为第5/7页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页